OPKO Health (OPK) 44th Annual J.P. Morgan Healthcare Conference summary

Business overview and strategic direction

• Focus shifted toward therapeutics, divesting 40% of clinical diagnostics to improve profitability and rebalance the balance sheet.

• Remaining diagnostics business is now break-even and profitable, centered in New York and New Jersey, with cancer diagnostics as a key area.

• ModeX Therapeutics, acquired in 2022, drives biotech innovation with multi-specific antibody and vaccine platforms.

• Strategic partnerships with Merck, Regeneron, and BARDA provide non-dilutive financing and expand the pipeline.

• International pharmaceutical and Rayaldee product lines are performing well, contributing to financial stability.

Financial performance and guidance

• Clinical lab business restructured for profitability, focusing on high-margin tests like 4Kscore, which grew over 15% in testing volume.

• Revenue growth for diagnostics projected at 3%-5% in 2026, with a $300 million base and single-digit EBITDA targeted.

• Cash flow positive operations expected by end of 2026.

• Over $100 million returned to shareholders in 2024; further guidance on stock buyback to be provided in February 2025.

Key pipeline and partnership updates

• Merck-partnered EBV vaccine completed phase 1; phase 2 decision expected in Q1, with significant financial milestones tied to progression.

• MDX-2001 (solid tumor T-cell engager) nearing phase 1A completion, with phase 1B to focus on responsive tumor types and further safety/efficacy data.

• MDX-2004, a first-in-class trispecific antibody, is in early clinical trials targeting immune rejuvenation, with broad potential applications.

• BARDA supports anti-COVID and pan-flu antibody programs, with phase 1 entry for COVID and ongoing FDA engagement for flu.

• Regeneron partnership targets four programs in obesity, metabolism, cancer, and immunology, with up to $1.2 billion in milestones; candidate selection expected by early 2026.